Navigation Links
Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
Date:2/7/2013

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf=Astoria in New York City.

Carl Spana , Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs on Monday, February 11, 2013 at 11:00 a.m. ET.

Palatin Technologies has reported positive top-line results in its recently completed Phase 2B clinical trial with bremelanotide for treatment of female sexual dysfunction, and is preparing for an end-of-Phase 2 meeting with the Food and Drug Administration in anticipation of commencing Phase 3 trials. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through February 18, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors and can be accessed here: http://www.bio.org/events/conferences/bio-ceo-investor-registration.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
7. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
9. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
10. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
11. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... While things have been quiet for ... company and provide a new outlook for the future. As a continued effort ... management with the retirement of Mr. Siegel as CEO. With the new adjustments in ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the course ... how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the ... dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will ...
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):